August 28, 2017Open Access

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Ceftazidime-avibactam may be a reasonable alternative to colistin in the treatment of K. pneumoniae carbapenemase-producing CRE infections. These findings require confirmation in a randomized controlled trial.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Duin et al. (Mon,) studied this question.

synapsesocial.com/papers/695d972bc9bd6ee9936c8383 https://doi.org/https://doi.org/10.1093/cid/cix783

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Colistin Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae:</i> Laboratory Detection and Impact on Mortality2016 · 194 citations
2Performance standards for antimicrobial susceptibility testing2019 · 4,381 citations
3Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary1999 · 320 citations
4Increasing prevalence and dissemination of NDM-1 metallo- -lactamase in India: data from the SMART study (2009)2011 · 165 citations
5Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality2020 · 102 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo